NEW SOUTH WALES

Australian green hydrogen electrolyser manufacturer, Hysata raises $111m USD led by bp Ventures and Templewater

Retrieved on: 
星期三, 五月 8, 2024

"This funding round, backed by a world class syndicate of investors, demonstrates the game changing impact Hysata is having on the green hydrogen landscape.

Key Points: 
  • "This funding round, backed by a world class syndicate of investors, demonstrates the game changing impact Hysata is having on the green hydrogen landscape.
  • "I am thrilled to have bp Ventures, Templewater and other new investors join ranks with our incredible existing shareholder base.
  • [2]
    Gareth Burns, Vice President of bp Ventures, added: "We know that green hydrogen can play a big role in decarbonisation.
  • Alfred Wong, Partner of Templewater, said: "We are thrilled at Templewater to be driving the green revolution, jointly leading this impactful investment in Hysata.

Prodigy Learning Officially Partners with Minecraft Education

Retrieved on: 
星期三, 五月 1, 2024

DUBLIN, May 1, 2024 /PRNewswire/ -- Irish-headquartered global education technology company, Prodigy Learning, is delighted to announce that it is officially joining forces with Minecraft Education to deliver engaging, easy to teach computer science curriculum & assessments within the Minecraft Education universe.

Key Points: 
  • DUBLIN, May 1, 2024 /PRNewswire/ -- Irish-headquartered global education technology company, Prodigy Learning, is delighted to announce that it is officially joining forces with Minecraft Education to deliver engaging, easy to teach computer science curriculum & assessments within the Minecraft Education universe.
  • Together we will be bringing credentialing into Minecraft Education in key, in-demand skills areas starting with Prodigy Learning's Coding in Minecraft program.
  • Coding in Minecraft by Prodigy Learning is a computer science credential program delivered through Minecraft Education.
  • Commenting, Andrew Flood, Chief Executive Officer of Prodigy Learning, said:
    "The partnership between Minecraft Education and Prodigy Learning marks a significant milestone in educational technology.

Australian Oilseeds, Largest APAC Producer of Non-Chemical, Non-GMO “Cold-Processing” Vegetable Oil, Enters into Contract with Woolworths and Costco Australia.

Retrieved on: 
星期四, 四月 25, 2024

New York, NY and Sydney, Australia, April 25, 2024 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited (Nasdaq: COOT) (“Australian Oilseeds” or “AOI”), the largest cold pressing oil plant in Australia and the APAC region, pressing strictly GMO-free conventional and organic oilseeds, through its subsidiary Good Earth Oils, today announced a new contract to supply Australia’s largest supermarket chain, Woolworths, with a range of non-GMO cold pressed extra virgin canola oils in all 960 stores across Australia. The new the contract value is approximately USD 3.5 million over the next eight months. Good Earth Oils has also secured a contract with Costco Australia valued at approximately USD 3 million to supply its non-GMO cold pressed extra virgin canola oil to Costco stores throughout Australia. Australian oilseed investments is also in discussions with other retail chains in both Australia and the United States for supply of its unique range of non-GMO cold pressed extra virgin vegetable oils that are processed without the use of harmful chemicals.

Key Points: 
  • The new the contract value is approximately USD 3.5 million over the next eight months.
  • Good Earth Oils has also secured a contract with Costco Australia valued at approximately USD 3 million to supply its non-GMO cold pressed extra virgin canola oil to Costco stores throughout Australia.
  • AOI’s carbon footprint is 40-50% lower than conventional canola oil processors, as a result of its methods that are committed to environmentally friendly pressing and grinding processes.
  • AOI commenced trading on the Nasdaq on March 22 under the Ticker symbol: COOT.

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Retrieved on: 
星期三, 四月 24, 2024

SYDNEY, AUSTRALIA, April 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

Key Points: 
  • Head and neck squamous cell carcinomas are a heterogenous disease that represent a high unmet medical need regardless of PD-L1 expression.
  • A total of 33 patients with recurrent or metastatic HNSCC have been enrolled into Cohort B.
  • The final number of evaluable patients in Cohort B is expected to be higher and additional data, including complete response rate, will be released together with Cohort A data.
  • Patients in Cohort A are stratified by CPS >1, CPS 1-19, and CPS >20, and the clinical results for these three CPS groups will be evaluated.

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Retrieved on: 
星期四, 四月 18, 2024

SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with the Centre for Human Drug Research (CHDR), a world-class institute in Leiden, the Netherlands specializing in cutting-edge early-stage clinical drug research, to perform a first-in-human clinical study of IMP761. This proprietary LAG-3 agonist antibody has been designed to restore balance to the immune system and address the underlying cause of many autoimmune diseases.

Key Points: 
  • This proprietary LAG-3 agonist antibody has been designed to restore balance to the immune system and address the underlying cause of many autoimmune diseases.
  • Subject to the relevant ethic and regulatory approvals, the single and multiple ascending dose, placebo-controlled, double-blind, Phase I study will enrol approximately 49 healthy volunteers, with the objective of assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD).
  • We’re very excited to be partnering with Immutep for this critical step in the development plan of their promising antibody.
  • IMP761 remains on target to enter the clinic mid-CY2024 and Immutep looks forward to providing more information as it approaches this important milestone.

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
星期三, 四月 17, 2024

SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the Company’s upcoming TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastatic non-small cell lung cancer (1L NSCLC).

Key Points: 
  • SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the Company’s upcoming TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastatic non-small cell lung cancer (1L NSCLC).
  • Immutep SVP, Regulatory & Strategy, Christian Mueller commented: “We continue to be pleased with our discussions with regulatory bodies around the world regarding our upcoming pivotal TACTI-004 trial and are thankful for the positive feedback and constructive guidance received by AEMPS.
  • Among the other items discussed at the meeting were general aspects of the trial design, including selection of the control arm and statistics, and the specificities of the patient population.
  • Additional interactions with regulatory agencies as well as with other stakeholders and potential partners are ongoing in a productive manner.

Stevie® Awards Announce Winners in 18th Annual Stevie® Awards for Sales & Customer Service

Retrieved on: 
星期一, 四月 15, 2024

FAIRFAX, Va., April 15, 2024 (GLOBE NEWSWIRE) -- Winners in the 18th annual Stevie® Awards for Sales & Customer Service, recognized as the world's top customer service awards and sales awards , were unveiled on Friday night at a gala ceremony in Las Vegas, Nevada USA, attended by more than 400 executives from around the world.

Key Points: 
  • FAIRFAX, Va., April 15, 2024 (GLOBE NEWSWIRE) -- Winners in the 18th annual Stevie® Awards for Sales & Customer Service, recognized as the world's top customer service awards and sales awards , were unveiled on Friday night at a gala ceremony in Las Vegas, Nevada USA, attended by more than 400 executives from around the world.
  • The 10 most-honored organizations in the 2024 Stevie Awards for Sales & Customer Service received Grand (“best in show”) Stevie Award trophies.
  • Winners of the 2024 People's Choice Stevie® Awards for Favorite Customer Service, announced on April 4, were also honored at the April 12 awards gala.
  • Nominations for the 2025 edition of the Stevie Awards for Sales & Customer Service will be accepted starting this July.

Vast Executes VS1 Engineering Contracts Advancing Toward Construction of 288 MWh Concentrated Solar Thermal Power Plant

Retrieved on: 
星期一, 四月 15, 2024

VS1 is a 30MW / 288 MWh CSP plant to be located in Port Augusta, South Australia.

Key Points: 
  • VS1 is a 30MW / 288 MWh CSP plant to be located in Port Augusta, South Australia.
  • Utilising Vast’s proprietary modular tower CSP v3.0 technology, VS1 will generate clean, low-cost, dispatchable power with over 8 hours of thermal energy storage.
  • The project is anticipated to create dozens of green manufacturing jobs, hundreds of jobs during construction and long-term plant operations roles.
  • Craig Wood, CEO of Vast said, "This is a major step forward for Vast and VS1, putting this historic CSP project on the path to construction.

Prodigy Learning Officially Partners with Minecraft Education

Retrieved on: 
星期三, 五月 1, 2024

Irish-headquartered global education technology company, Prodigy Learning, is delighted to announce that it is officially joining forces with Minecraft Education to deliver engaging, easy to teach computer science curriculum & assessments within the Minecraft Education universe.

Key Points: 
  • Irish-headquartered global education technology company, Prodigy Learning, is delighted to announce that it is officially joining forces with Minecraft Education to deliver engaging, easy to teach computer science curriculum & assessments within the Minecraft Education universe.
  • Prodigy Learning has just announced that it is officially joining forces with Minecraft Education to deliver engaging, easy to teach computer science curriculum & assessments within the Minecraft universe.
  • Coding in Minecraft by Prodigy Learning is a computer science credential program delivered through Minecraft Education.
  • Commenting, Andrew Flood, Chief Executive Officer of Prodigy Learning, said:
    “The partnership between Minecraft Education and Prodigy Learning marks a significant milestone in educational technology.

American Rare Earths’ Assay Results Expand Rare Earth Enrichment Within the Cowboy State Mine Area at Halleck Creek, Wyoming

Retrieved on: 
星期三, 四月 10, 2024

DENVER, April 10, 2024 (GLOBE NEWSWIRE) --  American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) the ‘Company’ today announced assay results from a recent mapping and sampling program in the Cowboy State Mine area. These results will allow the Company to target higher grade areas contiguous to the mining area within the recently published scoping study. These results complement the recently announced updated JORC resource of 2.34 billion tonnes2 and illustrate the consistently enriched mineralization at Halleck Creek.

Key Points: 
  • These results will allow the Company to target higher grade areas contiguous to the mining area within the recently published scoping study.
  • These results complement the recently announced updated JORC resource of 2.34 billion tonnes2 and illustrate the consistently enriched mineralization at Halleck Creek.
  • This mapping and sampling campaign within the Cowboy State Mine Area was focussed at a higher resolution.
  • The new mapping and sampling campaign provides better constraints on the geology of the Cowboy State mine area for future resource targeting and drill hole planning.